Multi-Institutional Reciprocal Validation Study of Computed Tomography Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer
Top Cited Papers
- 1 February 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (4) , 384-389
- https://doi.org/10.1200/jco.2006.07.7800
Abstract
Purpose Identify features on preoperative computed tomography (CT) scans to predict suboptimal primary cytoreduction in patients treated for advanced ovarian cancer in institution A. Reciprocally cross validate the predictors identified with those from two previously published cohorts from institutions B and C. Patients and Methods Preoperative CT scans from patients with stage III/IV epithelial ovarian cancer who underwent primary cytoreduction in institution A between 1999 and 2005 were retrospectively reviewed by radiologists blinded to surgical outcome. Fourteen criteria were assessed. Crossvalidation was performed by applying predictive model A to the patients from cohorts B and C, and reciprocally applying predictive models B and C to cohort A. Results Sixty-five patients from institution A were included. The rate of optimal cytoreduction (≤ 1 cm residual disease) was 78%. Diaphragm disease and large bowel mesentery implants were the only CT predictors of suboptimal cytoreduction on univariate (P < .02) and multivariate analysis (P < .02). In combination (model A), these predictors had a sensitivity of 79%, a specificity of 75%, and an accuracy of 77% for suboptimal cytoreduction. When model A was applied to cohorts B and C, accuracy rates dropped to 34% and 64%, respectively. Reciprocally, models B and C had accuracy rates of 93% and 79% in their original cohorts, which fell to 74% and 48% in cohort A. Conclusion The high accuracy rates of CT predictors of suboptimal cytoreduction in the original cohorts could not be confirmed in the cross validation. Preoperative CT predictors should be used with caution when deciding between surgical cytoreduction and neoadjuvant chemotherapy.Keywords
This publication has 28 references indexed in Scilit:
- Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysisGynecologic Oncology, 2006
- Ovarian cancer surgical resectability: Relative impact of disease, patient status, and surgeonGynecologic Oncology, 2006
- Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancerGynecologic Oncology, 2005
- The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinomaCancer, 2004
- Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancerInternational Journal of Gynecologic Cancer, 2004
- Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancerJournal of the American College of Surgeons, 2003
- CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancerInternational Journal of Gynecologic Cancer, 2003
- Can Serum CA-125 Levels Predict the Optimal Primary Cytoreduction in Patients with Advanced Ovarian Carcinoma?Gynecologic Oncology, 2002
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Ovarian carcinoma: value of CT in predicting success of debulking surgery.American Journal of Roentgenology, 1995